The phase 2 ImmunoCobiVem trial enrolled patients with unresectable or metastatic BRAFV600 mutant melanoma to receive BRAF/MEK inhibitor therapy with vemurafenib and cobimetinib for three months [81]. This evidence concerns the gene BRAF and melanoma.